Combining a new class of drug with two other compounds can significantly shrink lung tumors in mice and human cancer cells, new research shows. The study looked at G12C KRAS inhibitors, a new type of drug that targets a specific mutation that can cause cells to multiply uncontrollably and lead to fast-growing cancers.
